A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans.

The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has ...

The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

The Biden administration is looking to extend Medicare and Medicaid coverage to include obesity drugs like Wegovy and Zepbound. Weight loss drugs are now excluded from mandatory coverage.